Drug Trial Radar · NCT05320198
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jun 6, 2022
Primary completion
May 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Disc Medicine, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.
Conditions
- Myelofibrosis; Anemia
- Anemia
- Myelofibrosis
- Myelofibrosis Due to and Following Polycythemia Vera
- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Myelodysplastic Syndromes
Interventions
DISC-0974Drug
DISC-0974 is administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of DISC-0974 (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
- Safety and Tolerability of DISC-0974 (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
- Safety and Tolerability of DISC-0974 (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
- Safety and Tolerability of DISC-0974 (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
- Safety and Tolerability of DISC-0974 assessed through blood testing (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
- Safety and Tolerability of DISC-0974 assessed through urine testing (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
- Transfusion-dependent (TD) high cohort: transfusion independence (Phase 2 only)Time frame: From Day 1 to the end of treatment on Day 169
- TD low cohort: transfusion independence (Phase 2 only)Time frame: From Day 1 to the end of treatment on Day 169
- Non-transfusion-dependent (nTD) cohort: anemia response (Phase 2 only)Time frame: From Day 1 to the end of treatment on Day 169
Locations
35 sites in 2 countries. Site status is shown where the registry gives one.
Banner MD Anderson
Gilbert, Arizona · Recruiting
City of Hope - Duarte
Duarte, California · Recruiting
City of Hope - Lennar
Irvine, California · Recruiting
UCLA
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
University of Colorado Anschutz Medical Campus
Aurora, Colorado · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Sylvester Cancer Center - U Miami
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
Northwest Oncology
Rolling Meadows, Illinois · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Washington University St.Louis
St Louis, Missouri · Recruiting
START New Jersey
East Brunswick, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Montefiore
New York, New York · Recruiting
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina · Recruiting
Gabrail Cancer Center Research
Canton, Ohio · Terminated
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
Sargon Research - Pennsylvania Cancer Specialists and Research Center
Gettysburg, Pennsylvania · Withdrawn
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
MD Anderson
Houston, Texas · Recruiting
Baylor Scott & White
Temple, Texas · Recruiting
University of Washington
Seattle, Washington · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Linear Clinical Research
Nedlands, Australia · Recruiting
Western Health
Saint Albans, Australia · Recruiting
St. Vincent's Hospital
Sydney, Australia · Recruiting
Perth Blood Institute
West Perth, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.